News
CPRX
14.18
+1.00%
0.14
Catalyst Pharmaceuticals to Present at MDA Clinical & Scientific Conference Details of Registry for Study of Long-Term Safety and Quality of Life in Duchenne Muscular Dystrophy Patients Treated with AGAMREE
Catalyst Pharmaceuticals, Inc. Will present a poster at the 2024 MDA Clinical & Scientific Conference in Orlando. The poster is about the establishment of a registry to study long-term safety and quality of life in patients with Duchenne muscular dystrophy. The company is a commercial-stage biopharmaceutical company.
Barchart · 7h ago
Weekly Report: what happened at CPRX last week (0219-0223)?
Weekly Report · 1d ago
Catalyst Pharma Announces Promising Duchenne Drug Study Results
TipRanks · 5d ago
First Week of CPRX September 20th Options Trading
NASDAQ · 6d ago
Weekly Report: what happened at CPRX last week (0212-0216)?
Weekly Report · 02/19 10:40
Catalyst Pharmaceuticals to Report Fourth Quarter and Full-Year 2023 Financial Results on February 28, 2024
Catalyst Pharmaceuticals, Inc. Will release its fourth quarter and full-year 2023 financial results after the market close on February 28, 2024. The company is focused on in-licensing, developing, and commercializing novel medicines for patients living with rare diseases.
Barchart · 02/14 07:03
Weekly Report: what happened at CPRX last week (0205-0209)?
Weekly Report · 02/12 10:33
Weekly Report: what happened at CPRX last week (0129-0202)?
Weekly Report · 02/05 10:38
Weekly Report: what happened at CPRX last week (0122-0126)?
Weekly Report · 01/29 10:31
Catalyst Pharmaceuticals Inc: [Amend]Statement of acquisition of beneficial ownership by individuals
Press release · 01/25 16:04
Biotech And Pharma Diversification Pays Off
Seeking Alpha · 01/25 13:00
Catalyst Pharmaceuticals At A Crossroads: Firdapse Litigation And Agamree's Launch
Catalyst Pharmaceuticals, Inc. Is a biopharmaceutical company specializing in treatments for rare neurological and epileptic disorders. The company's main products are Firdapse and Fycompa. The launch of Agamree, an FDA-approved drug for Duchene muscular dystrophy, could significantly boost CPRX's revenues. CPRX is also dealing with lawsuits to stop the entry of a generic version of Firdapses into the market. I rate CPRX a "hold" for now.
Seeking Alpha · 01/23 00:45
Catalyst Pharmaceuticals Inc: [Amend]Statement of acquisition of beneficial ownership by individuals
Press release · 01/22 22:06
Jim Cramer Likes This Bank 'Very, Very Much,' Says Stock Is Up 7% Over Past 6 Months
Jim Cramer said Stanley Black & Decker is "very inexpensive" on "Mad Money Lightning Round" Cramer recommended to wait until the Fed cuts rates before buying ON Semiconductor Corporation. He said he's not a big fan of American Airlines Group Inc. The company is scheduled to report its fourth-quarter and full-year results on Thursday.
Benzinga · 01/22 13:43
Weekly Report: what happened at CPRX last week (0115-0119)?
Weekly Report · 01/22 10:34
Why Catalyst Pharmaceutical (CPRX) is a Top Momentum Stock for the Long-Term
NASDAQ · 01/18 14:50
3 Biotech Stocks to Watch as Forecasters Anticipate a $3.67 Trillion Industry by 2032
NASDAQ · 01/18 14:35
Catalyst Pharmaceuticals: Until The TEVA ANDA Is Resolved, There Is A Risk
Catalyst Pharmaceuticals, Inc. Has one approved product and another about to be launched. The company's market cap is low at $1.7bn. CPRX is facing a major patent challenge and has no major data catalysts or pipeline molecules. Until the patent issue is resolved, CPRX stock remains risky. The patent issue began after Teva Pharmaceutical questioned the validity of Firdapse.
Seeking Alpha · 01/17 19:13
Weekly Report: what happened at CPRX last week (0108-0112)?
Weekly Report · 01/15 10:31
Why Catalyst Pharmaceutical (CPRX) is a Top Growth Stock for the Long-Term
NASDAQ · 01/12 14:45
More
Webull provides a variety of real-time CPRX stock news. You can receive the latest news about Catalyst Pharmaceuticals Inc through multiple platforms. This information may help you make smarter investment decisions.
About CPRX
Catalyst Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company. The Company is focused on in-licensing, developing, and commercializing novel medicines for patients living with rare diseases. With the patient focus, the Company is engaged in developing a robust pipeline of cutting-edge, medicines for rare diseases. The Company's New Drug Application for FIRDAPSE (amifampridine) tablets 10 milligrams (mg) for the treatment of adults with Lambert-Eaton myasthenic syndrome (LEMS). The Company's FIRDAPSE is commercially available in the United States as a treatment for adults with LEMS. The Company also has FYCOMPA (perampanel) CIII, a prescription medicine approved in people with epilepsy aged four and older alone or with other medicines to treat partial-onset seizures with or without secondarily generalized seizures and with other medicines to treat primary generalized tonic-clonic seizures for people with epilepsy aged 12 and older.